Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
Read original at benzingaStocks · News reference
Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est
Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $555.000 million-$561.000 million vs $568.048 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 11:23 AM
- Checked
- Aug 13, 2026, 11:23 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
Read original at benzingaDA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
Read original at benzingaNeedham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
Read original at benzinga